CAMBRIDGE, Mass., May 30, 2024 Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president.
Q1 2024 EPS Estimates for Beam Therapeutics Inc. (NASDAQ:BEAM) Decreased by Leerink Partnrs themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024CAMBRIDGE, Mass., March 26, 2024 Beam Therapeutics Inc. , a biotechnology company developing precision genetic.
CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.